
Master and working cell banks for virus culture
Vaccination against disease is an integral part of prevention of communicable disease worldwide. Besides reducing incidence of a disease wheter it be in animals or humans, it also reduces social and economic burden worlwide.
The key consideration in preventing communicable disease and specifically dealing with a pandemic or epidemic outbreak of disease is timely production and deployment of vaccines.
The needs of vaccine manufacturing processes are to offer a broad portfolio as well as faster reaction times to deal with pandemics and epidemics.
Esco Aster is committed to providing vaccines that are accessible and affordable to the Asian and global population. It does so through its proprietary Tide Motion® platform that can rapidly speed up the manufacturing process of Viral vaccines.
Master and working cell banks for virus culture
Proprietary animal-component free culture media suitable for cultivation of certain cell subtrates
Optimisation and process development for cultivatio of cell subtrates for virus production
Process optimization and manufacturing of animal and human viral vaccines
Downstream processing for viral vaccines including concentration, purification and analytical services
Characterization and analysis of purified viral vaccines for endotoxins, host cell DNA and protein contamination and final viral titer
Sterility testing, fill and finish services
Cell banking and virus banking services
The Tide Motion&red; manufacturing platform offers a smooth and seamless vaccine production workflow.
In addition, a modularly integrated system with our Cell Processing Isolator (CPI), helps to localize vaccine prodction making it more affordable - in terms of CAPEX & OPEX - for developing countries by ensuring a smooth bioprocessing workflow.
With an aim of ensuring a reliability of vaccine supply and immunization to support the growing livestock and poultry industry. Tide Motion® Bioreactors are indeed the means of achieveing high-cell density working cell bank cultures (HD WCB) to support scalable production of veterinary vaccines.
The importance of human vaccines cannot be over-emphasized in terms of its impact on human health and lives. Timely vaccine production and deployment and its impact on human lives is crucial. Transmission of diseases from animals to humans and reassortment of viruses poses a significant threat globally and annual vaccination is an important strategy to prevent infection during pandemic outbreaks.
Culture conditions tend to be variable for different cell lines and very high cell densities; hence vaccines with a high titer which are capable of eliciting good immune responses have been achieved in TideXcell™ bioreactors.
As a consequence of high cell densities and high viral titers in the range of 8 log10 frequently the Tide Motion® bioreactors are able to effectively replace static culture systems as shown below:
Vaccine | 2D Culture system (No. of units) |
Tide Motion® Bioreactor (No. of units) |
---|---|---|
Hog cholera | Roller bottles (2500cm2) > 123 |
TideXcell™ - 002 (1) |
PEDV | T150-flasks > 285 | CelCradle™ - 500A (1) |
PRRSV | T175 - flasks > 132 | CelCrade™ - 500A (1) |
Vaccine | Roller Bottle (850 cm2, 2L) |
TideXcell™ (10L) |
---|---|---|
H5N1 | 1000-2000 | 1 |
H1N1 | 1000 | 1 |
CelCradle™ - 500A | Roller Bottles | Roux Bottles | |
---|---|---|---|
Media | 1000 ml | 4550 ml | 4550 ml |
Fetal Calf Serum | 100 ml | 455 ml | 455 ml |
Culture System | 1 | 26 | 13 |
Filtration | - | Y | Y |
Washing | - | Y | Y |
Packaging | - | Y | Y |
Sterilization | - | Y | Y |
Virus Titre | 106-7LD50/ml | 106LD50/ml | 106LD50/ml |
Equivalence | ||
---|---|---|
Titer of virus obtained from vs CelCradle™![]() |
||
32 roller bottles | = | 1 CelCradle-500 A |
(Volume = 8L)Titer = 7 X TCID50 per ml |
(Volume = 2.5L dilutted to 8L)Titer = 7.167 TCID50 per ml |
The vaccines against deltaFLU have been process optimized and scaled up at Esco Aster. The deltaFLU technology which is proprietary to one of Aster’s collaborators is an attenuated recombinant influenza virus that lacks the IFN –Y antagonist and thus has a natural self-adjuvanting action.
A Vero-cell based production process has yielded titers of >8.0log 10. An efficient scale-up, downstream processing and analysis of the final product ensures a smooth and seamless work flow as outlined below: